Related Experiment Video

Updated: May 6, 2026

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.0K

Glypican-3 antibodies: a new therapeutic target for liver cancer

Mingqian Feng1, Mitchell Ho1

  • 1Antibody Therapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

FEBS Letters
|October 22, 2013
PubMed

Insights

Glypican-3 (GPC3) shows promise as a liver cancer target. Current antibody therapies targeting GPC3 for hepatocellular carcinoma (HCC) are in development, with ongoing clinical trials for some agents.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Glypican-3 (GPC3) is an emerging therapeutic target for hepatocellular carcinoma (HCC).
  • The precise biological function of GPC3 in cancer remains largely unknown.
  • Several antibodies targeting GPC3 are in preclinical and clinical development for HCC treatment.

Purpose of the Study:

  • To review the evidence supporting GPC3 as a target in liver cancer.
  • To discuss the oncogenic role of GPC3 and the mechanisms of action of GPC3-targeting antibodies.
  • To evaluate potential challenges in GPC3-targeted cancer therapies.

Main Methods:

  • Literature review of current evidence on GPC3 in HCC.
  • Analysis of GPC3's oncogenic functions.
  • Evaluation of antibody-based therapeutic strategies against GPC3.

Main Results:

  • GPC3 is implicated in liver cancer development and progression.
  • Multiple antibodies, including human and humanized mouse versions, are being developed.
  • GC33 (humanized mouse antibody) is in Phase II clinical trials; MDX-1414 and HN3 (human antibodies) are in preclinical stages.

Conclusions:

  • GPC3 represents a promising target for novel hepatocellular carcinoma therapies.
  • Understanding GPC3's function is crucial for optimizing antibody-based treatments.
  • Challenges in GPC3-targeted therapy development need to be addressed for successful clinical translation.
Keywords:
GC33Glypican-3 (GPC3)HN3Heparan sulfate proteoglycanHepatocellular carcinomaYP7

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.5K
High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors19:02

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors

Published on: March 22, 2011

14.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129